Effective therapy with anti-TNF-α in patients with psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in the sera and skin lesions

Paola Cordiali-Fei, Elisabetta Trento, Giovanna D'Agosto, Valentina Bordignon, Anna Mussi, Marco Ardigò, Antonio Mastroianni, Antonella Vento, Francesco Solivetti, Enzo Berardesca, Fabrizio Ensoli

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Tumor necrosis factor-α (TNF-α) plays a central role in sustaining the inflammatory process in the skin as well as in the joints of patients with psoriasis and psoriatic arthritis. In fact, biological therapies based on monoclonal antibodies against TNF-α have been proven to be effective on both the arthropathy and the cutaneous symptoms of the disease. Among the several effects produced by TNF-α on keratinocytes there is the induction of expression of MMP-9,a matrix metalloproteinase (MMP) produced mainly by monocytes and macrophages. In this article we refer to the results of a study on the behavior of MMP-9 in the sera and in the lesional skin in association with effective therapy with infliximab. Measurements of TNF-α, MMP-2, vascular endothelial growth factor (VEGF), and E-selectin were also performed in the same samples. Eleven psoriatic patients included in a therapeutic protocol based on the administration of infliximab monotherapy were collected before treatment and after 6 and 12 weeks of therapy. Significant decrease of MMP-9 and MMP-2 levels in the sera was associated with clinical improvement and with the decrease of TNF-α, VEGF, and E-selectin, angiogenic molecules already known to be implicated in the clinical expression of psoriasis. The clinical amelioration of the cutaneous expression of psoriasis was significantly associated with the decrease of MMP-9, TNF-α, and E-selectin levels, spontaneously released by lesional biopsy samples before and after therapy, measured in the culture supernatants by immunoenzymatic assays. In addition, significant correlations were found between the clinical score and TNF-α, MMP-9, and E-selectin lesional production. MMP-9 levels were significantly correlated with those of TNF-α. Our findings show the existence of a direct relationship between MMP-9 and TNF-α production, strongly suggesting that MMP-9 may play a key role in the skin inflammatory process in psoriasis, while a different role may be attributed to MMP-2.

Original languageEnglish
Title of host publicationAnnals of the New York Academy of Sciences
Pages578-589
Number of pages12
Volume1110
DOIs
Publication statusPublished - Sep 2007

Publication series

NameAnnals of the New York Academy of Sciences
Volume1110
ISSN (Print)00778923
ISSN (Electronic)17496632

Fingerprint

Psoriatic Arthritis
Metalloproteases
Matrix Metalloproteinase 9
Skin
Tumor Necrosis Factor-alpha
Cytokines
E-Selectin
Serum
Psoriasis
Matrix Metalloproteinase 2
Therapeutics
Vascular Endothelial Growth Factor A
Biological Therapy
Biopsy
Joint Diseases
Macrophages
Matrix Metalloproteinases
Keratinocytes
Skin Diseases
Monocytes

Keywords

  • Infliximab
  • Lesional cytokines
  • MMP-2
  • MMP-9
  • Psoriasis
  • TNF-α

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Effective therapy with anti-TNF-α in patients with psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in the sera and skin lesions. / Cordiali-Fei, Paola; Trento, Elisabetta; D'Agosto, Giovanna; Bordignon, Valentina; Mussi, Anna; Ardigò, Marco; Mastroianni, Antonio; Vento, Antonella; Solivetti, Francesco; Berardesca, Enzo; Ensoli, Fabrizio.

Annals of the New York Academy of Sciences. Vol. 1110 2007. p. 578-589 (Annals of the New York Academy of Sciences; Vol. 1110).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Cordiali-Fei, P, Trento, E, D'Agosto, G, Bordignon, V, Mussi, A, Ardigò, M, Mastroianni, A, Vento, A, Solivetti, F, Berardesca, E & Ensoli, F 2007, Effective therapy with anti-TNF-α in patients with psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in the sera and skin lesions. in Annals of the New York Academy of Sciences. vol. 1110, Annals of the New York Academy of Sciences, vol. 1110, pp. 578-589. https://doi.org/10.1196/annals.1423.062
Cordiali-Fei, Paola ; Trento, Elisabetta ; D'Agosto, Giovanna ; Bordignon, Valentina ; Mussi, Anna ; Ardigò, Marco ; Mastroianni, Antonio ; Vento, Antonella ; Solivetti, Francesco ; Berardesca, Enzo ; Ensoli, Fabrizio. / Effective therapy with anti-TNF-α in patients with psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in the sera and skin lesions. Annals of the New York Academy of Sciences. Vol. 1110 2007. pp. 578-589 (Annals of the New York Academy of Sciences).
@inproceedings{326fd612381e4ec3a28c573b93619c46,
title = "Effective therapy with anti-TNF-α in patients with psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in the sera and skin lesions",
abstract = "Tumor necrosis factor-α (TNF-α) plays a central role in sustaining the inflammatory process in the skin as well as in the joints of patients with psoriasis and psoriatic arthritis. In fact, biological therapies based on monoclonal antibodies against TNF-α have been proven to be effective on both the arthropathy and the cutaneous symptoms of the disease. Among the several effects produced by TNF-α on keratinocytes there is the induction of expression of MMP-9,a matrix metalloproteinase (MMP) produced mainly by monocytes and macrophages. In this article we refer to the results of a study on the behavior of MMP-9 in the sera and in the lesional skin in association with effective therapy with infliximab. Measurements of TNF-α, MMP-2, vascular endothelial growth factor (VEGF), and E-selectin were also performed in the same samples. Eleven psoriatic patients included in a therapeutic protocol based on the administration of infliximab monotherapy were collected before treatment and after 6 and 12 weeks of therapy. Significant decrease of MMP-9 and MMP-2 levels in the sera was associated with clinical improvement and with the decrease of TNF-α, VEGF, and E-selectin, angiogenic molecules already known to be implicated in the clinical expression of psoriasis. The clinical amelioration of the cutaneous expression of psoriasis was significantly associated with the decrease of MMP-9, TNF-α, and E-selectin levels, spontaneously released by lesional biopsy samples before and after therapy, measured in the culture supernatants by immunoenzymatic assays. In addition, significant correlations were found between the clinical score and TNF-α, MMP-9, and E-selectin lesional production. MMP-9 levels were significantly correlated with those of TNF-α. Our findings show the existence of a direct relationship between MMP-9 and TNF-α production, strongly suggesting that MMP-9 may play a key role in the skin inflammatory process in psoriasis, while a different role may be attributed to MMP-2.",
keywords = "Infliximab, Lesional cytokines, MMP-2, MMP-9, Psoriasis, TNF-α",
author = "Paola Cordiali-Fei and Elisabetta Trento and Giovanna D'Agosto and Valentina Bordignon and Anna Mussi and Marco Ardig{\`o} and Antonio Mastroianni and Antonella Vento and Francesco Solivetti and Enzo Berardesca and Fabrizio Ensoli",
year = "2007",
month = "9",
doi = "10.1196/annals.1423.062",
language = "English",
isbn = "1573317098",
volume = "1110",
series = "Annals of the New York Academy of Sciences",
pages = "578--589",
booktitle = "Annals of the New York Academy of Sciences",

}

TY - GEN

T1 - Effective therapy with anti-TNF-α in patients with psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in the sera and skin lesions

AU - Cordiali-Fei, Paola

AU - Trento, Elisabetta

AU - D'Agosto, Giovanna

AU - Bordignon, Valentina

AU - Mussi, Anna

AU - Ardigò, Marco

AU - Mastroianni, Antonio

AU - Vento, Antonella

AU - Solivetti, Francesco

AU - Berardesca, Enzo

AU - Ensoli, Fabrizio

PY - 2007/9

Y1 - 2007/9

N2 - Tumor necrosis factor-α (TNF-α) plays a central role in sustaining the inflammatory process in the skin as well as in the joints of patients with psoriasis and psoriatic arthritis. In fact, biological therapies based on monoclonal antibodies against TNF-α have been proven to be effective on both the arthropathy and the cutaneous symptoms of the disease. Among the several effects produced by TNF-α on keratinocytes there is the induction of expression of MMP-9,a matrix metalloproteinase (MMP) produced mainly by monocytes and macrophages. In this article we refer to the results of a study on the behavior of MMP-9 in the sera and in the lesional skin in association with effective therapy with infliximab. Measurements of TNF-α, MMP-2, vascular endothelial growth factor (VEGF), and E-selectin were also performed in the same samples. Eleven psoriatic patients included in a therapeutic protocol based on the administration of infliximab monotherapy were collected before treatment and after 6 and 12 weeks of therapy. Significant decrease of MMP-9 and MMP-2 levels in the sera was associated with clinical improvement and with the decrease of TNF-α, VEGF, and E-selectin, angiogenic molecules already known to be implicated in the clinical expression of psoriasis. The clinical amelioration of the cutaneous expression of psoriasis was significantly associated with the decrease of MMP-9, TNF-α, and E-selectin levels, spontaneously released by lesional biopsy samples before and after therapy, measured in the culture supernatants by immunoenzymatic assays. In addition, significant correlations were found between the clinical score and TNF-α, MMP-9, and E-selectin lesional production. MMP-9 levels were significantly correlated with those of TNF-α. Our findings show the existence of a direct relationship between MMP-9 and TNF-α production, strongly suggesting that MMP-9 may play a key role in the skin inflammatory process in psoriasis, while a different role may be attributed to MMP-2.

AB - Tumor necrosis factor-α (TNF-α) plays a central role in sustaining the inflammatory process in the skin as well as in the joints of patients with psoriasis and psoriatic arthritis. In fact, biological therapies based on monoclonal antibodies against TNF-α have been proven to be effective on both the arthropathy and the cutaneous symptoms of the disease. Among the several effects produced by TNF-α on keratinocytes there is the induction of expression of MMP-9,a matrix metalloproteinase (MMP) produced mainly by monocytes and macrophages. In this article we refer to the results of a study on the behavior of MMP-9 in the sera and in the lesional skin in association with effective therapy with infliximab. Measurements of TNF-α, MMP-2, vascular endothelial growth factor (VEGF), and E-selectin were also performed in the same samples. Eleven psoriatic patients included in a therapeutic protocol based on the administration of infliximab monotherapy were collected before treatment and after 6 and 12 weeks of therapy. Significant decrease of MMP-9 and MMP-2 levels in the sera was associated with clinical improvement and with the decrease of TNF-α, VEGF, and E-selectin, angiogenic molecules already known to be implicated in the clinical expression of psoriasis. The clinical amelioration of the cutaneous expression of psoriasis was significantly associated with the decrease of MMP-9, TNF-α, and E-selectin levels, spontaneously released by lesional biopsy samples before and after therapy, measured in the culture supernatants by immunoenzymatic assays. In addition, significant correlations were found between the clinical score and TNF-α, MMP-9, and E-selectin lesional production. MMP-9 levels were significantly correlated with those of TNF-α. Our findings show the existence of a direct relationship between MMP-9 and TNF-α production, strongly suggesting that MMP-9 may play a key role in the skin inflammatory process in psoriasis, while a different role may be attributed to MMP-2.

KW - Infliximab

KW - Lesional cytokines

KW - MMP-2

KW - MMP-9

KW - Psoriasis

KW - TNF-α

UR - http://www.scopus.com/inward/record.url?scp=35748980280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35748980280&partnerID=8YFLogxK

U2 - 10.1196/annals.1423.062

DO - 10.1196/annals.1423.062

M3 - Conference contribution

C2 - 17911474

AN - SCOPUS:35748980280

SN - 1573317098

SN - 9781573317092

VL - 1110

T3 - Annals of the New York Academy of Sciences

SP - 578

EP - 589

BT - Annals of the New York Academy of Sciences

ER -